Effects of human atrial natriuretic peptide on myocardial performance and energetics in heart failure due to previous myocardial infarction

J Cardiol. 2015 Sep;66(3):232-8. doi: 10.1016/j.jjcc.2014.12.020. Epub 2015 Feb 23.

Abstract

Background: Human atrial natriuretic peptide (hANP) and spontaneous nitric oxide (NO) donor share cyclic guanosine monophosphate (cGMP) as a second messenger, but their effect on myocardium may differ. We compared the effect of hANP and sodium nitroprusside (SNP) on left ventricular (LV) mechano-energetics in heart failure (HF).

Methods: Ten patients with HF due to previous myocardial infarction (LV ejection fraction: 45±3%) were instrumented with conductance and coronary sinus thermodilution catheters. LV contractility (Ees: slope of end-systolic pressure-volume relation) and the ratio of LV stroke work (SW) to myocardial oxygen consumption (SW/MVO2=mechanical efficiency) were measured in response to intravenous infusion of ANP (0.05 μg/kg/min) or SNP (0.3 μg/kg/min) to lower blood pressure by at least 10 mmHg, and changes in plasma cGMP.

Results: SNP had no effect on Ees, SW, or MVO2, thus SW/MVO2 remained unchanged (40.54±5.84% to 36.59±5.72%, p=0.25). ANP increased Ees, and decreased MVO2 with preserved SW, resulting in improved SW/MVO2 (40.49±6.35% to 50.30±7.96%, p=0.0073). Infusion of ANP (10.42-34.95 pmol/ml, p=0.0003) increased cGMP levels, whereas infusion of SNP had no effect (10.42-12.23 pmol/ml, p=0.75).

Conclusions: Compared to SNP, the ANP-dependent increase in cGMP may ameliorate myocardial inotropy and energetics in HF.

Keywords: Cardiac mechano-energetics; Conductance catheter; Cyclic guanosine monophosphate; E(es).

MeSH terms

  • Atrial Natriuretic Factor / administration & dosage*
  • Blood Pressure / drug effects
  • Cyclic GMP / blood
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Humans
  • Infusions, Intravenous
  • Myocardial Contraction / drug effects
  • Myocardial Infarction / complications
  • Myocardium / metabolism
  • Nitric Oxide Donors / administration & dosage
  • Nitroprusside / administration & dosage
  • Oxygen Consumption
  • Stroke Volume / drug effects
  • Vasodilator Agents / administration & dosage*
  • Ventricular Dysfunction, Left / drug therapy

Substances

  • Nitric Oxide Donors
  • Vasodilator Agents
  • Nitroprusside
  • Atrial Natriuretic Factor
  • Cyclic GMP